At its meeting on 5 September 2022 the Transparency Council adopted position No. 84/2022 on the legitimacy of granting reimbursement approval for the drug Tript-OH (oxitriptan) for the indication: tetrahydrobiopterin deficiency.
At its meeting on 5 September 2022 the Transparency Council adopted position No. 84/2022 on the legitimacy of granting reimbursement approval for the drug Tript-OH (oxitriptan) for the indication: tetrahydrobiopterin deficiency.